Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538344 | 0.77 | SLC22A6 (0.58) | SLC22A6GPR84ATMPBRM1IMPDH2 | |
| SCHEMBL6535531 | 0.77 | SLC22A6 (0.58) | SLC22A6GPR84ATMPBRM1IMPDH2 | |
| SCHEMBL71774 | 0.77 | SLC22A6 (0.54) | SLC22A6GPR84ATMPBRM1IMPDH2 | |
| Hydrochloric Acid SCHEMBL29131483 | 0.74 | SLC22A6 (0.51) | SLC22A6GPR84ATMPBRM1IMPDH2 | |
| SCHEMBL28459212 | 0.74 | SLC22A6 (0.59) | SLC22A6GPR84ATMPBRM1IMPDH2 | |
| SCHEMBL1899742 | 0.74 | SLC22A6 (0.59) | SLC22A6GPR84ATMPBRM1MEN1 | |
| SCHEMBL28374800 | 0.74 | SLC22A6 (0.55) | SLC22A6GPR84ATMPBRM1IMPDH2 | |
| SCHEMBL28961088 | 0.74 | SLC22A6 (0.55) | SLC22A6GPR84ATMPBRM1IMPDH2 | |
| SCHEMBL25372633 | 0.73 | SLC22A6 (0.54) | SLC22A6GPR84ATMPBRM1IMPDH2 | |
| SCHEMBL7639542 | 0.73 | SLC22A6 (0.74) | SLC22A6GPR84ATMPBRM1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078029-B1 | ENANTIOMERICALLY PURE PHOSPHOINDOLE AS HIV INHIBITOR | IDENIX PHARMACEUTICALS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8486991-B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-7960428-B2 | (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| WO-2009102384-A2 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-2078029-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008042240-A9 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008042240-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| US-5276021-A | Anticholesterol or antilipemic agents | E. R. SQUIBB & SONS, INC. (US) | 1994-01-04 | — | — | US | disclosed |
| US-5091378-A | Anticholesterol agents | E. R. SQUIBB & SONS, INC. (US) | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | DUSP3, PNP, PPP5C | SLC22A6 4447/4885GPR84 4363/4885ATM 2432/4885 |
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | CMA1, CPA3, CPA1 | SLC22A6 2060/4885GPR84 1385/4885ATM 3244/4885 |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | DUSP3, PNP, PPP5C | SLC22A6 4447/4885GPR84 4363/4885ATM 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.